Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease.
16S metabarcoding
gut inflammation
inflammatory bowel disease
prebiotics
short-chain fatty acid
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
17
01
2020
revised:
06
04
2020
accepted:
11
05
2020
pubmed:
2
6
2020
medline:
12
8
2021
entrez:
2
6
2020
Statut:
ppublish
Résumé
Butyrate has shown anti-inflammatory and regenerative properties, providing symptomatic relief when orally supplemented in patients suffering from various colonic diseases. We investigated the effect of a colonic-delivery formulation of butyrate on the fecal microbiota of patients with inflammatory bowel diseases (IBDs). In this double-blind, placebo-controlled, pilot study, 49 IBD patients (n = 19 Crohn's disease, CD and n = 30 ulcerative colitis, UC) were randomized to oral administration of microencapsulated-sodium-butyrate (BLM) or placebo for 2 months, in addition to conventional therapy. Eighteen healthy volunteers (HVs) were recruited to provide a healthy microbiota model of the local people. Fecal microbiota from stool samples was assessed by 16S sequencing. Clinical disease activity and quality of life (QoL) were evaluated before and after treatment. At baseline, HVs showed a different microbiota composition compared with IBD patients. Sodium-butyrate altered the gut microbiota of IBD patients by increasing bacteria able to produce SCFA in UC patients (Lachnospiraceae spp.) and the butyrogenic colonic bacteria in CD patients (Butyricicoccus). In UC patients, QoL was positively affected by treatment. Sodium-butyrate supplementation increases the growth of bacteria able to produce SCFA with potentially anti-inflammatory action. The clinical impact of this finding requires further investigation.
Sections du résumé
BACKGROUND
Butyrate has shown anti-inflammatory and regenerative properties, providing symptomatic relief when orally supplemented in patients suffering from various colonic diseases. We investigated the effect of a colonic-delivery formulation of butyrate on the fecal microbiota of patients with inflammatory bowel diseases (IBDs).
METHODS
In this double-blind, placebo-controlled, pilot study, 49 IBD patients (n = 19 Crohn's disease, CD and n = 30 ulcerative colitis, UC) were randomized to oral administration of microencapsulated-sodium-butyrate (BLM) or placebo for 2 months, in addition to conventional therapy. Eighteen healthy volunteers (HVs) were recruited to provide a healthy microbiota model of the local people. Fecal microbiota from stool samples was assessed by 16S sequencing. Clinical disease activity and quality of life (QoL) were evaluated before and after treatment.
KEY RESULTS
At baseline, HVs showed a different microbiota composition compared with IBD patients. Sodium-butyrate altered the gut microbiota of IBD patients by increasing bacteria able to produce SCFA in UC patients (Lachnospiraceae spp.) and the butyrogenic colonic bacteria in CD patients (Butyricicoccus). In UC patients, QoL was positively affected by treatment.
CONCLUSIONS AND INFERENCES
Sodium-butyrate supplementation increases the growth of bacteria able to produce SCFA with potentially anti-inflammatory action. The clinical impact of this finding requires further investigation.
Identifiants
pubmed: 32476236
doi: 10.1111/nmo.13914
pmc: PMC7583468
doi:
Substances chimiques
Capsules
0
Histamine Antagonists
0
Butyric Acid
107-92-6
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13914Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd.
Références
Gut. 2006 Jun;55(6):749-53
pubmed: 16698746
J Bacteriol. 2004 Apr;186(7):2099-106
pubmed: 15028695
J Clin Gastroenterol. 1992 Jan;14(1):15-9
pubmed: 1556402
J Infect Dis. 2015 Jan 1;211(1):19-27
pubmed: 25057045
Clin Gastroenterol Hepatol. 2010 Apr;8(4):357-63
pubmed: 20096379
Pflugers Arch. 2018 Apr;470(4):571-598
pubmed: 29305650
Minerva Gastroenterol Dietol. 2008 Sep;54(3):231-8
pubmed: 18614971
Gut Microbes. 2018;9(3):189-201
pubmed: 29144833
Gut Microbes. 2016 Sep 2;7(5):435-42
pubmed: 27662587
World J Gastroenterol. 2011 Mar 28;17(12):1519-28
pubmed: 21472114
Inflamm Bowel Dis. 2008 Dec;14(12):1660-6
pubmed: 18623174
Aliment Pharmacol Ther. 2005 Nov 1;22(9):789-94
pubmed: 16225487
PLoS Pathog. 2013;9(11):e1003730
pubmed: 24278012
Prz Gastroenterol. 2013;8(6):350-3
pubmed: 24868283
Swiss Med Wkly. 2012 Jun 06;142:w13596
pubmed: 22674349
Nucleic Acids Res. 2014 Jan;42(Database issue):D643-8
pubmed: 24293649
PLoS Biol. 2018 Dec 4;16(12):e2006842
pubmed: 30513082
Neurogastroenterol Motil. 2009 Sep;21(9):952-e76
pubmed: 19460106
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Sci Rep. 2016 Oct 13;6:35216
pubmed: 27734914
PLoS One. 2013 Apr 22;8(4):e61217
pubmed: 23630581
Eur J Clin Invest. 2003 Mar;33(3):244-8
pubmed: 12641543
PLoS One. 2016 Jan 19;11(1):e0145503
pubmed: 26784747
Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(12):G900-10
pubmed: 24136789
Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209
pubmed: 28498155
IDCases. 2018 Oct 28;14:e00461
pubmed: 30425923
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16731-6
pubmed: 18936492
ISME J. 2014 Nov;8(11):2349-51
pubmed: 24824669
PLoS One. 2015 Mar 16;10(3):e0119441
pubmed: 25775453
Gut. 2016 Sep;65(9):1447-55
pubmed: 26353983
Colorectal Dis. 2013 Feb;15(2):204-9
pubmed: 22738315
Neurogastroenterol Motil. 2020 Oct;32(10):e13914
pubmed: 32476236
Inflamm Bowel Dis. 2012 May;18(5):968-84
pubmed: 21936031
PLoS One. 2014 Aug 21;9(8):e105592
pubmed: 25144201
Dig Dis Sci. 2000 May;45(5):976-81
pubmed: 10795763
Clin Nutr. 2010 Dec;29(6):738-44
pubmed: 20471725
PLoS Comput Biol. 2017 Nov 3;13(11):e1005752
pubmed: 29099853
Inflamm Bowel Dis. 2014 Aug;20(8):1407-15
pubmed: 24983982
Am J Gastroenterol. 1994 Feb;89(2):179-83
pubmed: 8304299
Compr Physiol. 2017 Dec 12;8(1):299-314
pubmed: 29357130
Gastroenterology. 1992 Jul;103(1):51-6
pubmed: 1612357
Diagn Microbiol Infect Dis. 2013 Mar;75(3):245-51
pubmed: 23276768
Aliment Pharmacol Ther. 2008 Jan 15;27(2):104-19
pubmed: 17973645
Front Microbiol. 2018 Sep 25;9:2247
pubmed: 30319571
Aliment Pharmacol Ther. 1995 Jun;9(3):309-13
pubmed: 7654893
Gut. 2014 Aug;63(8):1275-83
pubmed: 24021287
Am J Gastroenterol. 2010 Nov;105(11):2420-8
pubmed: 20648002
Neurogastroenterol Motil. 2011 Nov;23(11):975-9
pubmed: 21981302
Gut. 2005 Mar;54(3):364-8
pubmed: 15710984
J Inflamm Res. 2017 Jun 10;10:63-73
pubmed: 28652796
J Crohns Colitis. 2018 Jan 24;12(2):204-216
pubmed: 29373727